Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Zolpidem modulates GABA(A) receptor function in subthalamic nucleus.

Lei Chen1, Jun-Xia Xie, Kam-Shuen Fung

  • 1Department of Physiology, The Chinese University of Hong Kong, Shatin, Hong Kong, China. chenleiqd@163.com

Neuroscience Research
|March 6, 2007
PubMed
Summary

Zolpidem modulates inhibitory currents in the subthalamic nucleus, a key area for movement regulation. This drug shows potential for treating Parkinson's disease by influencing basal ganglia circuits.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

NLRP3 facilitates α-synuclein-induced dopaminergic neuronal senescence in a mouse model of Parkinson's disease through SATB1/DNA damage/p21 signaling pathway.

Acta pharmacologica Sinica·2025
Same author

The role of microglia in neurodegenerative diseases: from the perspective of ferroptosis.

Acta pharmacologica Sinica·2025
Same author

Epigenetic regulation of iron metabolism and ferroptosis in Parkinson's disease: Identifying novel epigenetic targets.

Acta pharmacologica Sinica·2025
Same author

Intranasal iron administration induces iron deposition, immunoactivation, and cell-specific vulnerability in the olfactory bulb of C57BL/6 mice.

Zoological research·2025
Same author

Elevated CXCL1 triggers dopaminergic neuronal loss in the substantia nigra of C57BL/6J mice: Evaluation of a novel Parkinsonian mouse model.

Zoological research·2025
Same author

Cell senescence induced by toxic interaction between α-synuclein and iron precedes nigral dopaminergic neuron loss in a mouse model of Parkinson's disease.

Acta pharmacologica Sinica·2023

Area of Science:

  • Neuroscience
  • Pharmacology
  • Movement Disorders

Background:

  • The subthalamic nucleus is crucial for regulating movement within the basal ganglia circuitry.
  • Zolpidem, a GABA(A) receptor agonist, shows promise in treating certain Parkinson's disease patients.
  • High concentrations of zolpidem binding sites exist in the rat subthalamic nucleus.

Purpose of the Study:

  • To investigate how zolpidem affects GABA(A) receptor-mediated inhibitory synaptic currents in the subthalamic nucleus.
  • To explore the potential therapeutic role of zolpidem in Parkinson's disease.

Main Methods:

  • Whole-cell patch clamp recordings were employed to measure synaptic currents.
  • Experiments involved applying zolpidem at different concentrations (100 nM and 1 microM).

Related Experiment Videos

  • The effect of the benzodiazepine antagonist flumazenil was assessed to confirm specificity.

    • Main Results:

    • Zolpidem (100 nM) prolonged the decay and rise times of miniature inhibitory postsynaptic currents without altering amplitude or frequency.
    • Flumazenil blocked zolpidem's potentiation, confirming action at the benzodiazepine site.
    • Zolpidem (1 microM) increased decay time, rise time, amplitude, and frequency of these currents.
    • In vivo, zolpidem microinjection into the subthalamic nucleus induced contralateral rotation in rats.

    Conclusions:

    • Zolpidem modulates GABAergic inhibition in the subthalamic nucleus.
    • These findings support further research into zolpidem for Parkinson's disease treatment.
    • The study provides a mechanistic rationale for zolpidem's observed benefits in parkinsonian patients.